Core Points - Company received a successful GMP inspection from the European Directorate for the Quality of Medicines (EDQM) for its active pharmaceutical ingredient (API) [1] - The inspection took place from May 14 to May 16, 2025, focusing on the API Olmesartan Medoxomil with CEP number CEP2014-121 [1] - The company has now obtained the inspection certificate issued by EDQM [1]